Abstract: Objective To explore the feasibility and necessity for China’s pharmaceutical enterprises to conduct exterritorial medicine commissioning manufacture. Methods Compare and analyze the laws and regulations governing medicine commissioning manufacture in China, Japan, and other countries. Results and Conclusion Chinese government and pharmaceutical enterprises should seize the opportunities to improve their capacity in exterritorial medicine commissioning manufacture.